Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Staphylococcal Infections | 10 | 2020 | 76 | 3.090 |
Why?
|
Bacteremia | 7 | 2023 | 65 | 2.990 |
Why?
|
Anti-Bacterial Agents | 20 | 2023 | 324 | 2.950 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 5 | 2020 | 32 | 2.350 |
Why?
|
Microbial Sensitivity Tests | 16 | 2023 | 80 | 1.770 |
Why?
|
Staphylococcus | 2 | 2023 | 10 | 1.670 |
Why?
|
Methicillin Resistance | 5 | 2023 | 22 | 1.540 |
Why?
|
Staphylococcus aureus | 8 | 2023 | 53 | 1.510 |
Why?
|
Bacteriological Techniques | 9 | 2018 | 17 | 1.480 |
Why?
|
Pseudomonas aeruginosa | 2 | 2020 | 35 | 1.440 |
Why?
|
Bacterial Proteins | 5 | 2022 | 90 | 1.160 |
Why?
|
Humans | 60 | 2023 | 32024 | 1.160 |
Why?
|
Bacteria | 5 | 2018 | 48 | 1.090 |
Why?
|
beta-Lactamases | 3 | 2022 | 13 | 1.070 |
Why?
|
Pneumocystis carinii | 2 | 2020 | 6 | 1.040 |
Why?
|
Epstein-Barr Virus Infections | 2 | 2022 | 10 | 0.990 |
Why?
|
Gonorrhea | 2 | 2020 | 12 | 0.900 |
Why?
|
Cross Infection | 4 | 2019 | 55 | 0.890 |
Why?
|
BK Virus | 1 | 2022 | 6 | 0.870 |
Why?
|
Klebsiella pneumoniae | 2 | 2020 | 14 | 0.870 |
Why?
|
Polyomavirus Infections | 1 | 2022 | 21 | 0.850 |
Why?
|
Acinetobacter baumannii | 1 | 2022 | 6 | 0.840 |
Why?
|
Influenza, Human | 3 | 2019 | 122 | 0.830 |
Why?
|
Diagnostic Errors | 3 | 2012 | 44 | 0.830 |
Why?
|
Penicillin-Binding Proteins | 2 | 2020 | 3 | 0.830 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2022 | 94 | 0.820 |
Why?
|
Reagins | 1 | 2022 | 3 | 0.810 |
Why?
|
Syphilis | 1 | 2022 | 10 | 0.810 |
Why?
|
Neisseria gonorrhoeae | 2 | 2020 | 8 | 0.770 |
Why?
|
Pseudomonas Infections | 1 | 2020 | 14 | 0.750 |
Why?
|
Drug Contamination | 2 | 2018 | 6 | 0.720 |
Why?
|
Azithromycin | 1 | 2020 | 15 | 0.720 |
Why?
|
Kidney Transplantation | 2 | 2022 | 517 | 0.720 |
Why?
|
beta-Lactam Resistance | 1 | 2020 | 2 | 0.710 |
Why?
|
Cytomegalovirus | 1 | 2020 | 30 | 0.700 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2020 | 70 | 0.690 |
Why?
|
Blood Platelets | 4 | 2009 | 39 | 0.690 |
Why?
|
Communicable Diseases | 1 | 2019 | 20 | 0.690 |
Why?
|
Immunocompromised Host | 5 | 2020 | 51 | 0.690 |
Why?
|
Syringes | 1 | 2018 | 5 | 0.660 |
Why?
|
Antifungal Agents | 5 | 2018 | 40 | 0.650 |
Why?
|
Anesthetics | 1 | 2018 | 18 | 0.650 |
Why?
|
Operating Rooms | 1 | 2018 | 35 | 0.640 |
Why?
|
Strongyloidiasis | 1 | 2017 | 3 | 0.610 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 18 | 0.600 |
Why?
|
Drug Resistance, Bacterial | 3 | 2020 | 47 | 0.560 |
Why?
|
Gram-Negative Bacteria | 2 | 2013 | 8 | 0.500 |
Why?
|
Gram-Negative Bacterial Infections | 2 | 2013 | 14 | 0.490 |
Why?
|
Molecular Diagnostic Techniques | 3 | 2020 | 11 | 0.470 |
Why?
|
Clinical Laboratory Techniques | 3 | 2021 | 24 | 0.450 |
Why?
|
Platelet Transfusion | 4 | 2009 | 16 | 0.440 |
Why?
|
Shiga Toxin | 1 | 2012 | 2 | 0.440 |
Why?
|
Shiga-Toxigenic Escherichia coli | 1 | 2012 | 3 | 0.440 |
Why?
|
Chromatography, Affinity | 1 | 2012 | 15 | 0.440 |
Why?
|
Daptomycin | 1 | 2012 | 2 | 0.430 |
Why?
|
Enterococcus faecalis | 1 | 2012 | 12 | 0.430 |
Why?
|
Feces | 1 | 2012 | 40 | 0.430 |
Why?
|
Enterococcus faecium | 1 | 2012 | 5 | 0.430 |
Why?
|
Escherichia coli Infections | 1 | 2012 | 39 | 0.420 |
Why?
|
Fatal Outcome | 6 | 2018 | 82 | 0.410 |
Why?
|
Carbapenems | 2 | 2022 | 7 | 0.400 |
Why?
|
Mycoses | 2 | 2011 | 21 | 0.400 |
Why?
|
Fungi | 1 | 2011 | 9 | 0.380 |
Why?
|
Laboratories, Hospital | 1 | 2010 | 3 | 0.360 |
Why?
|
Pathology, Molecular | 1 | 2010 | 16 | 0.360 |
Why?
|
Bacterial Infections | 3 | 2006 | 52 | 0.360 |
Why?
|
Mycobacterium Infections | 1 | 2010 | 1 | 0.360 |
Why?
|
Corynebacterium Infections | 1 | 2010 | 3 | 0.360 |
Why?
|
Mycobacterium | 1 | 2010 | 3 | 0.360 |
Why?
|
Endocarditis, Bacterial | 1 | 2010 | 10 | 0.360 |
Why?
|
Herpesvirus 4, Human | 2 | 2022 | 9 | 0.340 |
Why?
|
Bone Marrow Diseases | 1 | 2009 | 2 | 0.340 |
Why?
|
Pneumocystis Infections | 1 | 2009 | 2 | 0.340 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 2009 | 4 | 0.340 |
Why?
|
United States | 8 | 2020 | 3938 | 0.330 |
Why?
|
Male | 16 | 2020 | 19195 | 0.330 |
Why?
|
Bone Marrow | 1 | 2009 | 70 | 0.320 |
Why?
|
Time Factors | 6 | 2018 | 2152 | 0.310 |
Why?
|
Amphotericin B | 3 | 2018 | 12 | 0.310 |
Why?
|
Lung Diseases, Fungal | 2 | 2018 | 7 | 0.310 |
Why?
|
Drug Resistance, Microbial | 3 | 2022 | 14 | 0.310 |
Why?
|
Adult | 13 | 2020 | 9366 | 0.300 |
Why?
|
Polymerase Chain Reaction | 2 | 2021 | 197 | 0.300 |
Why?
|
Blood Transfusion | 2 | 2004 | 74 | 0.290 |
Why?
|
Influenza A virus | 2 | 2019 | 22 | 0.290 |
Why?
|
Drug Resistance, Fungal | 2 | 2003 | 3 | 0.280 |
Why?
|
Fluconazole | 2 | 2003 | 8 | 0.280 |
Why?
|
Child, Preschool | 4 | 2020 | 1269 | 0.260 |
Why?
|
Female | 18 | 2020 | 19953 | 0.260 |
Why?
|
Erythromycin | 2 | 2002 | 7 | 0.260 |
Why?
|
Sepsis | 2 | 2004 | 158 | 0.260 |
Why?
|
Sensitivity and Specificity | 4 | 2020 | 594 | 0.250 |
Why?
|
Blood Component Transfusion | 1 | 2004 | 10 | 0.250 |
Why?
|
Streptococcus pyogenes | 2 | 2003 | 16 | 0.250 |
Why?
|
Seasons | 2 | 2019 | 87 | 0.240 |
Why?
|
DNA, Viral | 2 | 2022 | 54 | 0.240 |
Why?
|
Streptococcal Infections | 2 | 2003 | 22 | 0.240 |
Why?
|
Laboratories | 1 | 2023 | 15 | 0.230 |
Why?
|
Middle Aged | 11 | 2019 | 11868 | 0.230 |
Why?
|
Length of Stay | 2 | 2023 | 318 | 0.230 |
Why?
|
Costs and Cost Analysis | 1 | 2023 | 100 | 0.220 |
Why?
|
Candidiasis | 1 | 2003 | 5 | 0.220 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2003 | 9 | 0.220 |
Why?
|
Candida albicans | 1 | 2003 | 12 | 0.220 |
Why?
|
Esophageal Diseases | 1 | 2003 | 7 | 0.220 |
Why?
|
Mitosporic Fungi | 1 | 2003 | 2 | 0.220 |
Why?
|
Cephalosporins | 1 | 2023 | 9 | 0.220 |
Why?
|
Antibodies, Bacterial | 2 | 2022 | 32 | 0.220 |
Why?
|
Viral Load | 1 | 2022 | 70 | 0.210 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2022 | 21 | 0.210 |
Why?
|
Pneumonia | 2 | 2020 | 67 | 0.210 |
Why?
|
Streptococcus pneumoniae | 1 | 2002 | 40 | 0.210 |
Why?
|
Cell Culture Techniques | 2 | 2014 | 174 | 0.210 |
Why?
|
Syphilis Serodiagnosis | 1 | 2022 | 4 | 0.200 |
Why?
|
Treponema pallidum | 1 | 2022 | 7 | 0.200 |
Why?
|
Animals | 4 | 2020 | 7466 | 0.200 |
Why?
|
Immunoassay | 1 | 2021 | 16 | 0.190 |
Why?
|
Carrier State | 1 | 2020 | 23 | 0.190 |
Why?
|
Bacterial Typing Techniques | 2 | 2014 | 17 | 0.190 |
Why?
|
Membrane Proteins | 1 | 2002 | 257 | 0.190 |
Why?
|
Antibodies, Viral | 1 | 2020 | 58 | 0.180 |
Why?
|
Cerebrospinal Fluid Otorrhea | 1 | 2020 | 3 | 0.180 |
Why?
|
Cefixime | 1 | 2020 | 4 | 0.180 |
Why?
|
HIV Seronegativity | 1 | 2020 | 6 | 0.180 |
Why?
|
Osteomyelitis | 1 | 2020 | 22 | 0.180 |
Why?
|
Pharynx | 1 | 2020 | 14 | 0.180 |
Why?
|
Penicillins | 1 | 2020 | 11 | 0.180 |
Why?
|
Tetracycline | 1 | 2020 | 13 | 0.180 |
Why?
|
Ceftriaxone | 1 | 2020 | 14 | 0.180 |
Why?
|
Arthritis, Infectious | 1 | 2020 | 24 | 0.180 |
Why?
|
Virology | 1 | 2020 | 1 | 0.180 |
Why?
|
Mycological Typing Techniques | 1 | 2020 | 1 | 0.180 |
Why?
|
Bronchoalveolar Lavage | 1 | 2020 | 14 | 0.180 |
Why?
|
Oxacillin | 1 | 2020 | 4 | 0.180 |
Why?
|
Hospitals | 1 | 2020 | 103 | 0.180 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2020 | 6 | 0.180 |
Why?
|
Cytomegalovirus Infections | 1 | 2020 | 48 | 0.170 |
Why?
|
Enterobacteriaceae | 2 | 2017 | 11 | 0.170 |
Why?
|
Health Facilities | 1 | 2019 | 9 | 0.170 |
Why?
|
Clindamycin | 3 | 2007 | 22 | 0.170 |
Why?
|
North Carolina | 3 | 2020 | 1516 | 0.170 |
Why?
|
Drug Packaging | 1 | 2018 | 5 | 0.160 |
Why?
|
Homosexuality, Male | 1 | 2020 | 84 | 0.160 |
Why?
|
Blood Preservation | 3 | 2009 | 11 | 0.160 |
Why?
|
Child | 6 | 2016 | 2441 | 0.160 |
Why?
|
Ascomycota | 1 | 2018 | 4 | 0.160 |
Why?
|
Diagnosis, Differential | 1 | 2020 | 518 | 0.150 |
Why?
|
Strongyloides stercoralis | 1 | 2017 | 3 | 0.150 |
Why?
|
Piperacillin | 1 | 2017 | 6 | 0.150 |
Why?
|
Penicillanic Acid | 1 | 2017 | 6 | 0.150 |
Why?
|
Antiparasitic Agents | 1 | 2017 | 6 | 0.150 |
Why?
|
Cryptococcosis | 1 | 2017 | 5 | 0.150 |
Why?
|
Ivermectin | 1 | 2017 | 9 | 0.150 |
Why?
|
Pharmacists | 1 | 2018 | 20 | 0.150 |
Why?
|
Plateletpheresis | 2 | 2009 | 3 | 0.150 |
Why?
|
Physicians | 1 | 2019 | 158 | 0.150 |
Why?
|
Case-Control Studies | 1 | 2020 | 897 | 0.150 |
Why?
|
Colony Count, Microbial | 3 | 2010 | 18 | 0.140 |
Why?
|
Culture Media | 2 | 2009 | 47 | 0.140 |
Why?
|
Aged | 5 | 2019 | 10340 | 0.140 |
Why?
|
Predictive Value of Tests | 3 | 2020 | 878 | 0.140 |
Why?
|
Sphingomonas | 1 | 2015 | 3 | 0.130 |
Why?
|
Meningitis | 1 | 2015 | 9 | 0.130 |
Why?
|
Virulence | 2 | 2007 | 22 | 0.130 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 407 | 0.130 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2016 | 47 | 0.130 |
Why?
|
Community-Acquired Infections | 2 | 2007 | 31 | 0.130 |
Why?
|
Adolescent | 5 | 2016 | 3526 | 0.130 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2015 | 4 | 0.130 |
Why?
|
Mucormycosis | 1 | 2014 | 2 | 0.120 |
Why?
|
Autoantibodies | 1 | 2015 | 49 | 0.120 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2014 | 10 | 0.120 |
Why?
|
Influenza B virus | 1 | 2014 | 20 | 0.120 |
Why?
|
Young Adult | 4 | 2016 | 2615 | 0.120 |
Why?
|
Chile | 3 | 2006 | 7 | 0.120 |
Why?
|
Electrophoresis | 1 | 2014 | 7 | 0.120 |
Why?
|
Multiple Organ Failure | 2 | 2014 | 10 | 0.120 |
Why?
|
Fluorescent Antibody Technique | 1 | 2014 | 91 | 0.110 |
Why?
|
Microscopy, Fluorescence | 1 | 2014 | 88 | 0.110 |
Why?
|
Computational Biology | 1 | 2014 | 91 | 0.110 |
Why?
|
United States Food and Drug Administration | 2 | 2020 | 45 | 0.110 |
Why?
|
Diabetes Complications | 1 | 2014 | 177 | 0.110 |
Why?
|
Hematuria | 1 | 2012 | 11 | 0.110 |
Why?
|
Lactobacillus | 1 | 2012 | 14 | 0.110 |
Why?
|
Urinalysis | 1 | 2012 | 27 | 0.110 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2014 | 251 | 0.110 |
Why?
|
Gentamicins | 1 | 2012 | 5 | 0.100 |
Why?
|
Peritonitis | 1 | 2012 | 14 | 0.100 |
Why?
|
Mupirocin | 1 | 2012 | 3 | 0.100 |
Why?
|
Catheter-Related Infections | 1 | 2012 | 10 | 0.100 |
Why?
|
Anti-Infective Agents, Local | 1 | 2012 | 15 | 0.100 |
Why?
|
Antibiotic Prophylaxis | 1 | 2012 | 37 | 0.100 |
Why?
|
Peritoneal Dialysis | 1 | 2012 | 26 | 0.100 |
Why?
|
Hyphae | 1 | 2011 | 1 | 0.100 |
Why?
|
Cerebrospinal Fluid | 1 | 2011 | 17 | 0.100 |
Why?
|
Unnecessary Procedures | 1 | 2011 | 16 | 0.100 |
Why?
|
Cushing Syndrome | 1 | 2010 | 1 | 0.090 |
Why?
|
Nocardia asteroides | 1 | 2010 | 2 | 0.090 |
Why?
|
Carcinoid Tumor | 1 | 2010 | 14 | 0.090 |
Why?
|
Rifampin | 1 | 2010 | 8 | 0.090 |
Why?
|
Staphylococcus epidermidis | 1 | 2010 | 6 | 0.090 |
Why?
|
Ventriculostomy | 1 | 2010 | 11 | 0.090 |
Why?
|
Cerebrospinal Fluid Shunts | 1 | 2010 | 7 | 0.090 |
Why?
|
Minocycline | 1 | 2010 | 11 | 0.090 |
Why?
|
Urine | 1 | 2011 | 64 | 0.090 |
Why?
|
Coated Materials, Biocompatible | 1 | 2010 | 18 | 0.090 |
Why?
|
Education, Continuing | 1 | 2010 | 6 | 0.090 |
Why?
|
Mass Screening | 1 | 2012 | 264 | 0.090 |
Why?
|
Organizational Innovation | 1 | 2010 | 31 | 0.090 |
Why?
|
Calorimetry | 1 | 2009 | 4 | 0.090 |
Why?
|
Blood | 1 | 2009 | 14 | 0.090 |
Why?
|
Phlebotomy | 1 | 2009 | 16 | 0.090 |
Why?
|
Equipment Contamination | 1 | 2009 | 12 | 0.090 |
Why?
|
Geotrichosis | 1 | 2009 | 1 | 0.090 |
Why?
|
Geotrichum | 1 | 2009 | 1 | 0.090 |
Why?
|
Echinocandins | 1 | 2009 | 6 | 0.090 |
Why?
|
Lipopeptides | 1 | 2009 | 6 | 0.090 |
Why?
|
Neutropenia | 1 | 2009 | 30 | 0.090 |
Why?
|
Phenotype | 2 | 2002 | 639 | 0.090 |
Why?
|
DNA, Bacterial | 2 | 2007 | 27 | 0.090 |
Why?
|
Bacterial Capsules | 1 | 2009 | 4 | 0.080 |
Why?
|
Microscopy, Atomic Force | 1 | 2009 | 5 | 0.080 |
Why?
|
Bacterial Adhesion | 1 | 2009 | 6 | 0.080 |
Why?
|
Respiratory Syncytial Virus, Human | 1 | 2008 | 3 | 0.080 |
Why?
|
Respiratory Syncytial Virus Infections | 1 | 2008 | 10 | 0.080 |
Why?
|
Spleen | 1 | 2009 | 86 | 0.080 |
Why?
|
Ustilaginales | 1 | 2008 | 3 | 0.080 |
Why?
|
Fungemia | 1 | 2008 | 3 | 0.080 |
Why?
|
Short Bowel Syndrome | 1 | 2008 | 16 | 0.080 |
Why?
|
Antiviral Agents | 1 | 2008 | 108 | 0.080 |
Why?
|
Skin | 1 | 2009 | 210 | 0.070 |
Why?
|
Catheterization, Central Venous | 1 | 2008 | 62 | 0.070 |
Why?
|
Molecular Epidemiology | 1 | 2007 | 20 | 0.070 |
Why?
|
Vancomycin Resistance | 1 | 2007 | 8 | 0.070 |
Why?
|
Evolution, Molecular | 1 | 2007 | 34 | 0.070 |
Why?
|
Antibodies, Monoclonal | 1 | 2008 | 244 | 0.070 |
Why?
|
Lung Neoplasms | 1 | 2010 | 409 | 0.070 |
Why?
|
Disease Reservoirs | 1 | 2006 | 2 | 0.070 |
Why?
|
Hospitals, University | 1 | 2006 | 32 | 0.070 |
Why?
|
Bartonella henselae | 1 | 2006 | 2 | 0.070 |
Why?
|
Serotyping | 2 | 2003 | 19 | 0.070 |
Why?
|
Quality Control | 1 | 2006 | 44 | 0.070 |
Why?
|
Cats | 1 | 2006 | 108 | 0.070 |
Why?
|
Electrophoresis, Gel, Pulsed-Field | 2 | 2003 | 11 | 0.060 |
Why?
|
Blood Donors | 1 | 2004 | 14 | 0.060 |
Why?
|
Contact Tracing | 2 | 2020 | 9 | 0.060 |
Why?
|
Clostridium difficile | 1 | 2004 | 12 | 0.060 |
Why?
|
Intestinal Diseases | 1 | 2004 | 16 | 0.060 |
Why?
|
Clostridium Infections | 1 | 2004 | 9 | 0.060 |
Why?
|
Methicillin | 1 | 2004 | 3 | 0.060 |
Why?
|
Sterilization | 1 | 2003 | 2 | 0.060 |
Why?
|
Erythrocytes | 1 | 2003 | 48 | 0.060 |
Why?
|
Pharyngeal Diseases | 1 | 2003 | 9 | 0.060 |
Why?
|
Candidiasis, Oral | 1 | 2003 | 10 | 0.060 |
Why?
|
Cryptococcus neoformans | 1 | 2003 | 2 | 0.060 |
Why?
|
Candida | 1 | 2003 | 7 | 0.060 |
Why?
|
CD4 Lymphocyte Count | 1 | 2003 | 32 | 0.060 |
Why?
|
Risk Factors | 2 | 2018 | 3869 | 0.050 |
Why?
|
Methyltransferases | 1 | 2002 | 5 | 0.050 |
Why?
|
Phenazines | 1 | 2002 | 1 | 0.050 |
Why?
|
Serologic Tests | 1 | 2002 | 11 | 0.050 |
Why?
|
Gentian Violet | 1 | 2002 | 3 | 0.050 |
Why?
|
False Negative Reactions | 1 | 2002 | 20 | 0.050 |
Why?
|
Prospective Studies | 3 | 2014 | 2283 | 0.050 |
Why?
|
Infant | 2 | 2016 | 1061 | 0.050 |
Why?
|
Antibodies, Neutralizing | 1 | 2020 | 19 | 0.050 |
Why?
|
Immunoglobulin G | 2 | 2015 | 121 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 261 | 0.050 |
Why?
|
Alternaria | 1 | 2018 | 1 | 0.040 |
Why?
|
Patient Care Management | 1 | 2018 | 18 | 0.040 |
Why?
|
Knee | 1 | 2018 | 33 | 0.040 |
Why?
|
Biopsy, Fine-Needle | 1 | 2017 | 53 | 0.040 |
Why?
|
Program Evaluation | 1 | 2018 | 186 | 0.040 |
Why?
|
Patient Care Team | 1 | 2018 | 130 | 0.040 |
Why?
|
Attitude of Health Personnel | 1 | 2018 | 182 | 0.030 |
Why?
|
Disease Outbreaks | 2 | 2008 | 43 | 0.030 |
Why?
|
Aged, 80 and over | 2 | 2014 | 4000 | 0.030 |
Why?
|
Cryoglobulins | 1 | 2015 | 5 | 0.030 |
Why?
|
Erythrocyte Transfusion | 1 | 2015 | 35 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2017 | 765 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2016 | 673 | 0.030 |
Why?
|
Reagent Strips | 1 | 2012 | 4 | 0.030 |
Why?
|
False Positive Reactions | 1 | 2012 | 31 | 0.030 |
Why?
|
Pseudomonas | 1 | 2012 | 6 | 0.030 |
Why?
|
Emergency Service, Hospital | 1 | 2016 | 473 | 0.030 |
Why?
|
Survival Analysis | 1 | 2013 | 488 | 0.020 |
Why?
|
Retrospective Studies | 2 | 2012 | 3523 | 0.020 |
Why?
|
Nocardia Infections | 1 | 2010 | 2 | 0.020 |
Why?
|
Adrenocorticotropic Hormone | 1 | 2010 | 19 | 0.020 |
Why?
|
Prosthesis-Related Infections | 1 | 2010 | 22 | 0.020 |
Why?
|
Agar | 1 | 2009 | 1 | 0.020 |
Why?
|
Chromogenic Compounds | 1 | 2009 | 1 | 0.020 |
Why?
|
Color | 1 | 2009 | 12 | 0.020 |
Why?
|
Surface Properties | 1 | 2009 | 32 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2015 | 1324 | 0.020 |
Why?
|
Water | 1 | 2009 | 56 | 0.020 |
Why?
|
Population Surveillance | 1 | 2008 | 125 | 0.020 |
Why?
|
Cohort Studies | 1 | 2012 | 1831 | 0.020 |
Why?
|
Models, Biological | 1 | 2009 | 391 | 0.020 |
Why?
|
Blood-Borne Pathogens | 1 | 2006 | 8 | 0.020 |
Why?
|
Seroepidemiologic Studies | 1 | 2006 | 10 | 0.020 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2006 | 14 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2006 | 298 | 0.020 |
Why?
|
Evaluation Studies as Topic | 1 | 2005 | 45 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2013 | 3317 | 0.020 |
Why?
|
Pharyngitis | 1 | 2003 | 10 | 0.010 |
Why?
|
Empyema, Pleural | 1 | 2003 | 7 | 0.010 |
Why?
|
Disease Transmission, Infectious | 1 | 2003 | 17 | 0.010 |
Why?
|
Pneumonia, Bacterial | 1 | 2003 | 32 | 0.010 |
Why?
|
Shock, Septic | 1 | 2003 | 26 | 0.010 |
Why?
|
Family Health | 1 | 2003 | 76 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2003 | 286 | 0.010 |
Why?
|
Genotype | 1 | 2003 | 734 | 0.010 |
Why?
|